OasisLMS

This Tumor session was recorded live at the 2025 AANS Annual Scientific Meeting.

Adjuvant therapies, such as stereotactic radiosurgery, laser interstitial and targeted systemic treatment, continue to be refined to offer advances in local disease control and overall survival. Participants will learn from debates between leaders in the field and discussions of the future of multidisciplinary skull base tumor treatment.

Speakers: Ahmed Altaf, Carolina Benjamin, Carlos David, Christina Jackson, Debraj Mukherjee, Daniel Prevedello, Adam Robin, Eric Suero Molina, Keki Turel, Alaa Turkistani, Gelareh Zadeh

The AANS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AANS designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The last date to claim credit is 06/26/2027.

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the AANS must ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational activities. In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Education, the AANS is required to disclose to the activity audience the relevant financial relationships of the planners, faculty and any other individual in a position to control content of this activity.

Those who have disclosed a relationship with ineligible companies are listed below.

All disclosed financial relationships have been mitigated in accordance with ACCME standards.

Name	Relationship/Company
Carlos David	KOGENT: Stock Shareholder (excluding mutual funds) (Ongoing); NextGen Biologics: Stock Shareholder (excluding mutual funds) (Ongoing)
Eric Suero Molina	Carl Zeiss Meditech AG: Grant/Research Support (Ongoing)

Planners, faculty and any other individuals in control of content not listed have indicated that they have no relevant financial relationships or conflict of interest to disclose for this activity.